Warren Eric — SEC insider filings
SEC reporting owner CIK 1916048. 35 insider filings on record with FilingPulse; latest filed 2026-09-22.
Transaction summary — filings shown
Covers all 35 filings on record, filed 2022-03-16 to 2026-09-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,000 shares, $7,460 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 29 legs across 29 filings — 146,502 shares, $3,360,559 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 104,124 shares @ $25.90 ($2,696,322) in Mineralys Therapeutics, Inc., filed 2026-06-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | Chief Commercial Officer | 4 | — | 4 legs · 126,437 sh · $3,298,532 | 8 |
| Esperion Therapeutics, Inc. (ESPR) | Chief Commercial Officer | 31 | 1 leg · 1,000 sh · $7,460 | 25 legs · 20,065 sh · $62,028 | 8 |
Insider filings — Warren Eric
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-22 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Option exercise (M): 7,438 @ $13.24 · Sale (S): 7,438 @ $28.12 · Option exercise (M): 7,438 (derivative) @ $0 | EDGAR |
| 2026-08-25 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Option exercise (M): 7,437 @ $13.24 · Sale (S): 7,437 @ $25.98 · Option exercise (M): 7,437 (derivative) @ $0 | EDGAR |
| 2026-07-23 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Option exercise (M): 7,438 @ $13.24 · Sale (S): 7,438 @ $26.87 · Option exercise (M): 7,438 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Option exercise (M): 104,124 @ $13.24 · Sale (S): 104,124 @ $25.90 · Option exercise (M): 104,124 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 108 @ $0.98 | EDGAR |
| 2025-03-19 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 2,433 @ $1.49 | EDGAR |
| 2025-03-17 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 213,000 @ $0 · Grant/award (A): 191,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 239 @ $1.87 | EDGAR |
| 2024-12-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 2,234 @ $2.43 | EDGAR |
| 2024-11-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 197 @ $2.17 | EDGAR |
| 2024-10-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 107 @ $2.12 | EDGAR |
| 2024-09-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 2,608 @ $1.78 | EDGAR |
| 2024-08-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 211 @ $1.95 | EDGAR |
| 2024-07-19 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 108 @ $2.59 | EDGAR |
| 2024-06-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 2,540 @ $2.86 | EDGAR |
| 2024-05-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 192 @ $2.48 | EDGAR |
| 2024-03-15 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 100,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-09-21 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 742 @ $1.25 | EDGAR |
| 2023-08-21 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 243 @ $1.41 | EDGAR |
| 2023-07-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 106 @ $1.58 | EDGAR |
| 2023-06-22 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 603 @ $1.48 | EDGAR |
| 2023-05-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 219 @ $1.62 | EDGAR |
| 2023-04-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 115 @ $1.28 | EDGAR |
| 2023-03-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 526 @ $1.78 | EDGAR |
| 2023-03-15 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 22,300 @ $0 · Grant/award (A): 94,500 (derivative) @ $0 | EDGAR |
| 2023-03-08 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 5,090 @ $5.05 | EDGAR |
| 2022-10-19 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 107 @ $7.69 | EDGAR |
| 2022-09-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 255 @ $6.92 | EDGAR |
| 2022-08-31 | 4 | Esperion Therapeutics, Inc. (ESPR) | Purchase (P): 1,000 @ $7.46 | EDGAR |
| 2022-08-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 199 @ $6.82 | EDGAR |
| 2022-07-20 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 431 @ $6.58 | EDGAR |
| 2022-06-21 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 256 @ $4.90 | EDGAR |
| 2022-06-09 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
| 2022-05-18 | 4 | Esperion Therapeutics, Inc. (ESPR) | Sale (S): 196 @ $5.98 | EDGAR |
| 2022-03-16 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 13,000 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2022-03-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1916048 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs